Covidien Loses Bid To Block Generic Restoril
Covidien Ltd. has been thwarted in its attempt to block URL Pharma Inc. from launching a generic version of the sleep disorder drug Restoril when a U.S. Food and Drug Administration...To view the full article, register now.
Already a subscriber? Click here to view full article